| Literature DB >> 35700984 |
Dae Chul Suh1,2, Soo Jeong1, Yun Hyeok Choi1, Su Min Cho1, Su Young Yun1, A Yeun Son1, Young Min Lim3, Boseong Kwon1, Yunsun Song1.
Abstract
PURPOSE: Reversible aggravation of myelopathy symptoms was observed after the intake of taurine-rich foods in patients with venous congestive myelopathy (VCM) caused by a spinal arteriovenous shunt (SAVS), and the taurine-challenge test was applied to demonstrate an association between taurine and VCM.Entities:
Keywords: Central nervous system vascular malformations; Hyperemia; Magnetic resonance imaging; Spinal cord disease; Taurine
Year: 2022 PMID: 35700984 PMCID: PMC9256475 DOI: 10.5469/neuroint.2022.00129
Source DB: PubMed Journal: Neurointervention ISSN: 2093-9043
Fig. 1.Candidate selection process diagram for the taurine challenge test. VCM, venous congestive myelopathy; F/U, follow-up; SI, signal intensity; MRI, magnetic resonance imaging; PSMS, pain-sensory-motor-sphincter score.
Fig. 2.An adult patient with reversible aggravation myelopathy symptoms that developed after intake of taurine-rich foods and disappeared after treatment. (A) A fusion 3D angiogram of both internal iliac arteries shows a sacral dural arteriovenous shunt with retrograde regurgitation via the radicular vein (arrow). (B) Venous congestive myelopathy was noted in the spinal cord on a T2-weighted image in magnetic resonance imaging (MRI). Note the signal voids of the vessels around and below the swollen spinal cord (arrow). (C) Follow-up MRI after shunt treatment shows the disappearance of high signal intensities on the spinal cord and also revealed no symptom development after the intake of taurine-rich food.
Summary of 4 VCM patients with a history of aggravation after the intake of taurine-rich foods
| Case | Age/Sex | Dx. | Lesion level | Steroid[ | Taurine-rich foods | Pre-PSMS | Post-PSMS | Pre–Post PSMS[ | Taurine challenge after Tx. | Free taurinerich food intake | F/U (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 42/M | SDAVF | S2 | Yes | Webfoot octopus, squid, small octopus, Bacchus® 2,000 mg | 3 | 1 | 2 | Done at 24 months | Yes | 24 |
| 2 | 71/M | SDAVF | T10 | NA | Webfoot octopus, squid, small octopus, crab, scallops | 4 | 2 | 2 | Done at 26 months | Yes | 26 |
| 3 | 63/F | SEDAVF | L2 | NA | Bacchus® 1,000 mg | 4 | 1 | 3 | Done at 48 months | Yes | 48 |
| 4 | 45/M | SDAVF | L1 | No | Bacchus® 2,000 mg | 5 | 0 | 5 | Done at 76 months | Yes | 76 |
Bacchus® (Dong-A Pharmaceutical, Seoul, Korea).
VCM, venous congestive myelopathy; Dx., diagnosis; PSMS, pain-sensory-motor-sphincter score; Tx., treatment; F/U, follow-up; M, male; F, female; SDAVF, spinal dural arteriovenous fistula; SEDAVF, spinal epidural arteriovenous fistula; NA, not available.
History of symptom aggravation after steroid medications.
Difference between Pre- and Post-PSMS score.
Fig. 3.Schematic diagram of possible mechanism related to the vasogenic edema in venous congestive myelopathy (VCM). (A) Arterialized venous engorgement around the spinal cord and cord swelling in the spinal dural arteriovenous shunt. (B) Cross-section of the swollen spinal cord showed venous engorgement of arterialized veins with decreased arterial perfusion in the VCM. (C) Magnified view of the vasogenic edema shows increased hydrostatic pressure caused by venous hypertension that opens Aquaporin-4 water channels in the foot processes of astrocytes and induces perivascular water movement (dotted arrows). Damage of blood-spinal cord barrier at the venous perivascular space (large asterisk) and capillary wall (small asterisk) finally increases interstitial fluid in the extracellular space leading to vasogenic edema.